The global non-invasive prenatal testing market size was valued at USD 5.37 billion in 2025 and is projected to grow from USD 6.10 billion in 2026 to USD 17.01 billion by 2034, registering a CAGR of 13.67% during the forecast period from 2026 to 2034. North America dominated the non-invasive prenatal testing market with a market share of 42.5% in 2025.
The non-invasive prenatal testing (NIPT) market encompasses products, technologies, and laboratory services used to screen for fetal chromosomal abnormalities through the analysis of cell-free fetal DNA in a pregnant woman's blood. NIPT is widely used to assess conditions such as Down syndrome, Edwards syndrome, and Patau syndrome without posing risks to the fetus. The market is driven by advances in genomic technologies, increasing maternal age, and growing adoption of early prenatal screening worldwide.
By Product
By Instrument
By Consumables
By Application
Download a Free Sample To learn more about this report,
Greater Focus on Rare Chromosomal Abnormalities
Growing interest in rare chromosomal abnormalities is expanding prenatal screening beyond the commonly assessed trisomies toward less frequent chromosomal changes. This transition is supported by broader cfDNA analysis and improved sequencing, allowing laboratories to identify additional abnormalities that may have previously required more targeted diagnostic approaches. A 2025 study involving 94,125 NIPT cases identified rare chromosomal abnormalities in 336 pregnancies, highlighting the additional findings that broader screening can detect.
Expansion of Genome-Wide Screening
Advances in sequencing are moving NIPT from targeted chromosome screening toward broader genome-wide assessment. This transition allows testing to examine additional chromosomal regions and identify copy-number changes that may not be captured through standard trisomy screening, increasing the range of findings available from a single maternal blood sample. A 2025 study reported that genome-wide cfDNA screening can detect clinically relevant chromosomal abnormalities beyond trisomies 21, 18, and 13, supporting its growing role in prenatal testing.
Safer Prenatal Screening and NIPT Integration Drive Market
Expectant parents’ preference for screening methods with lower procedural risk is increasing demand for non-invasive prenatal testing. Maternal blood-based screening offers a safer approach than invasive procedures for assessing the risk of common fetal chromosomal abnormalities. This preference is supporting wider use of NIPT services across prenatal care settings. For example, healthcare providers can use NIPT as an early screening option before recommending diagnostic procedures when clinically appropriate.
Broader integration of NIPT into prenatal care is increasing demand for testing services from hospitals, obstetric clinics, and diagnostic laboratories. Wider clinical use gives healthcare providers an additional screening option and expands the patient base receiving cell-free DNA testing. This shift is supporting greater utilization of NIPT laboratories and related sample-processing services. For example, ACOG guidance published in 2025 states that prenatal genetic screening options should be discussed and offered to all pregnant patients, supporting wider access to screening.
High Testing Costs and Limited Prenatal Testing Infrastructure Restrain Market Expansion
High testing costs and limited insurance coverage increase the financial burden on expectant parents, especially in regions where NIPT is largely paid out of pocket. Higher expenses can make patients and healthcare providers more cautious about recommending or choosing NIPT. As a result, lower affordability can slow testing adoption and restrict market growth.
Limited access to advanced prenatal testing infrastructure restricts the availability of NIPT in rural areas and regions with less-developed healthcare systems. Shortages of specialized laboratories, trained professionals, and reliable sample-handling networks can delay testing and reduce service accessibility. Consequently, uneven infrastructure can slow market penetration and limit broader adoption.
NIPT for Multiple Pregnancies and Cost-Effective Solutions Offers Growth Opportunities
Diagnostic laboratories, genomic testing companies, and NIPT providers can develop specialized testing solutions for twin and multiple pregnancies. Revenue avenues include premium testing services, customized screening panels, and partnerships with hospitals and fertility clinics. Companies such as Natera and BGI Genomics already offer NIPT solutions covering twin pregnancies.
Diagnostic companies and sequencing providers can target price-sensitive markets through streamlined workflows and lower-cost NIPT solutions. Revenue opportunities include higher testing volumes, affordable screening packages, and expansion into underserved regions. Companies such as BGI Genomics and Natera can leverage scalable testing platforms to support broader market access.
Short Equipment Replacement Cycles, Technology Obsolescence, and Event Seasonality Limit Market Growth
Rapid changes in cameras, touchscreens, AI effects, and photo-sharing software require operators to upgrade equipment frequently. Companies that delay upgrades can lose customers to providers offering newer interactive experiences, while frequent replacement increases operational pressure.
Photo booth demand is closely tied to weddings, festivals, corporate events, and holiday periods, creating uneven revenue throughout the year. This makes workforce planning, equipment utilization, and cash-flow management difficult for rental companies and can slow expansion into new markets.
The consumables segment accounted for a share of 46.9% in 2025 due to their essential role in sample collection, preparation, and genetic analysis during NIPT procedures. Their recurring use across testing workflows also supports consistent demand and strengthens their market position.
The consumables segment is expected to grow at a CAGR of 14.4%, driven by the increasing number of NIPT procedures and recurring demand across testing workflows. Instrument supports market growth through the use of advanced systems for sample processing and genetic analysis. Services contribute through laboratory testing, data analysis, and clinical support for NIPT.
Request Customizationto receive a tailored report.
The NGS systems segment accounted for a share of 34.5% in 2025 due to their high accuracy, scalability, and ability to analyze multiple genetic targets in a single test. Their broad use in prenatal genetic screening also supports their strong market position.
The NGS systems segment is expected to grow at a CAGR of 14.7%, driven by increasing adoption of high-throughput sequencing for accurate and comprehensive prenatal genetic screening. Ultrasound Devices support prenatal assessment through imaging-based fetal monitoring. PCR Instruments enable targeted amplification of genetic material for prenatal testing. Microarray supports detection of chromosomal abnormalities through high-resolution genetic analysis. Others contribute through complementary instruments used across NIPT workflows.
The assay kits & reagents segment accounted for a share of 72.4% in 2025 due to their essential role in processing and analyzing maternal blood samples during NIPT. Their recurring use across testing procedures also supports consistent demand and market dominance.
The assay kits & reagents segment is expected to grow at a CAGR of 14.8%, driven by the rising adoption of NIPT and the recurring need for reliable kits and reagents for genetic analysis. Their essential role in accurate sample processing and screening further supports demand.
The trisomy segment accounted for a share of 68.3% in 2025 due to the widespread use of NIPT for screening common chromosomal abnormalities such as trisomy 21, 18, and 13. The high clinical focus on early detection of these conditions also supports its strong market position.
The microdeletion syndrome segment is expected to grow at a CAGR of 15.1%, driven by increasing awareness of rare chromosomal abnormalities and the growing use of advanced NIPT methods for their detection. Others contribute to market growth through NIPT applications targeting additional genetic and chromosomal abnormalities.
The hospitals segment accounted for a share of 68.3% in 2025 due to their access to advanced diagnostic facilities, trained healthcare professionals, and integrated prenatal care services. Their established role in prenatal screening and patient management also supports strong adoption of NIPT.
The diagnostic laboratories segment is expected to grow at a CAGR of 14.7%, driven by the increasing outsourcing of NIPT services and rising demand for specialized prenatal genetic testing. Clinics also contribute to market growth by offering accessible prenatal screening and referral services for NIPT.
Speak to an Analystto discuss market opportunities.
The North America non-invasive prenatal testing market accounted for the largest regional share of 42.5% in 2025. This dominance is supported by increasing demand for early prenatal screening, advanced healthcare infrastructure, and growing awareness of non-invasive testing options. The U.S. non-invasive prenatal testing market is expected to benefit from continued demographic ageing, as the U.S. Census Bureau projects the U.S. population aged 65 and older to reach 88.8 million by 2060, which can contribute to a higher share of pregnancies among older mothers and support demand for advanced prenatal screening.
Similarly, the Canada non-invasive prenatal testing market is supported by ongoing population ageing, as Statistics Canada projects that the number of women aged 65 and older will continue to increase through 2050, supporting the need for advanced prenatal screening among pregnancies at higher genetic-risk levels.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific non-invasive prenatal testing market is expected to grow at a CAGR of 15.6% during the forecast period, showcasing the fastest-growing regional market. This growth is supported by rising awareness of prenatal screening, increasing healthcare investments, and growing adoption of advanced genetic testing technologies.In the Japan non-invasive prenatal testing market, Japan’s National Institute of Population and Social Security Research projects that the country’s births will remain on a declining trend, with the medium-fertility projection indicating about 741,000 births in 2030, potentially increasing the importance of advanced prenatal screening for pregnancies with higher genetic-risk considerations. In the China non-invasive prenatal testing market, China’s National Bureau of Statistics reported that prenatal screening coverage reached 93.5% in 2024, up 2.2 percentage points from 2023, indicating continued expansion of prenatal screening services that can support adoption of advanced non-invasive testing.
In the South Korea non-invasive prenatal testing market, Statistics Korea projects that South Korea’s population will decline to 51.31 million by 2030, while the country’s official projections also indicate continued demographic pressure from low fertility, supporting greater focus on prenatal and maternal healthcare for pregnancies. Meanwhile, the India non-invasive prenatal testing market could benefit from a large potential population requiring prenatal care and screening services, as a UNFPA projection estimates that the number of pregnancies in India could reach approximately 35 million annually by 2030.
The Europe non-invasive prenatal testing market accounted for a regional share of 27.8% in 2025. The region is supported by growing awareness of prenatal screening, well-established healthcare systems, and increasing adoption of advanced genetic testing technologies. In the U.K. non-invasive prenatal testing market, the U.K. Office for National Statistics projects that around 6.79 million people will be born between mid-2022 and mid-2032, indicating a substantial future population requiring prenatal care and screening services.
In the Germany non-invasive prenatal testing market, Germany’s Federal Statistical Office projects that the average age of women at childbirth could reach around 31.7 years by 2070 under its moderate fertility scenario, supporting continued demand for advanced prenatal screening as maternal age increases. Meanwhile, the France non-invasive prenatal testing market is expected to benefit from the projected increase in the average age of women at childbirth from 31.2 years in 2025 to 33.0 years by 2050 under its central projection, supporting the need for advanced prenatal screening.
The Middle East and Africa non-invasive prenatal testing market is expected to grow at a CAGR of 10.9% during the forecast period, showcasing the fastest-growing regional market. This growth is supported by rising awareness of prenatal screening, improving healthcare infrastructure, and increasing access to advanced genetic testing services.
In the U.A.E. non-invasive prenatal testing market, the U.A.E.’s Federal Competitiveness and Statistics Centre projects the country’s population to reach 10.5 million by 2030, supporting continued demand for maternal healthcare and prenatal screening services. Similarly, the Africa non-invasive prenatal testing market could benefit from demographic growth, as the United Nations projects that sub-Saharan Africa’s population will reach around 2.2 billion by 2050, increasing the potential need for maternal healthcare and prenatal screening services across the region.
The non-invasive prenatal testing (NIPT) market is moderately fragmented, with competition spread across global diagnostic companies, sequencing technology providers, reproductive genomics specialists, clinical laboratories, and regional testing providers. The market includes both established multinational companies and specialized regional testing providers, creating competition across technology, service capabilities, pricing, and market access.The leading players include Natera, Inc., Illumina, Inc., Laboratory Corporation of America Holdings, F. Hoffmann-La Roche AG, and Quest Diagnostics Incorporated**, which collectively account for approximately 65% of the market. Established players compete through test accuracy, clinical validation, advanced sequencing capabilities, broad testing portfolios, laboratory networks, and healthcare provider relationships, while emerging players focus on cost-effective testing, faster turnaround times, specialized screening panels, and localized services.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Europe Tangential Flow Filtration Market Size, Share & Trends | Industry Report, 2034
Asia Pacific Genetic Testing Market Size, 2034
North America TB Diagnostics Market Size & Trends Analysis, 2034
U.S Direct to Consumer Laboratory Testing Market Size, Share and Forecast to 2034
Vaccines Market Size, Share, Growth, Analysis, Report, 2034
Biomaterials Market Size, Share, Growth, Analysis, Report, 2034
We are featured on:
sales@straitsresearch.com